Compare GOSS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOSS | XLO |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | 162 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.6M | 56.9M |
| IPO Year | 2018 | 2021 |
| Metric | GOSS | XLO |
|---|---|---|
| Price | $10.56 | $8.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 1 |
| Target Price | $4.19 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 8.2M | 8.9K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,471,000.00 | $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $201.64 | $168.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $0.11 | $0.46 |
| 52 Week High | $12.52 | $9.90 |
| Indicator | GOSS | XLO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.